Sidney Jones, MD
Endocrinology, Diabetes & Metabolism · Chaska, MNNPI 1508806811
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $58,791 of the $66,523 with a category attached, or 88.4%. AstraZeneca accounts for 67.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $39,946 and has fallen 99.7% since, to $120 in 2025. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 118 payments — averaging $563.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$45K
- Sanofi-aventis U.S. LLC$9K
- Lilly USA, LLC$8K
- Boehringer Ingelheim$4K
- Intuity Medical Inc$118
- Sequel Med Tech, LLC$70
- plus $258 from 9 others
What the payments were for
- Consulting fees$3,6005%
- Speaking & faculty fees$58,79188%
- Travel & lodging$2,1663%
- Food & beverage$1,8773%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 58 | $44,945 |
| Sanofi-aventis U.S. LLC | 15 | $8,667 |
| Lilly USA, LLC | 17 | $8,407 |
| Boehringer Ingelheim | 10 | $4,058 |
| Intuity Medical Inc | 4 | $118 |
| Sequel Med Tech, LLC | 1 | $70 |
| Novo Nordisk | 2 | $66 |
| BETA Bionics, Inc. | 3 | $44 |
| Dexcom, Inc. | 2 | $38 |
| Senseonics, Incorporated | 1 | $23 |
| Cequr Corporation | 1 | $20 |
| Amgen | 1 | $19 |
| Abbott | 1 | $18 |
| Pfizer | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$44,354
- JARDIANCE$12,233
- SOLIQUA 100/33$4,823
- TOUJEO$3,664
How this compares
$66,523 in reported general payments places this provider in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 569 | $624,960 |
| OzempicSemaglutide | 528 | $544,726 |
| FarxigaDapagliflozin Propanediol | 236 | $271,397 |
| JardianceEmpagliflozin | 228 | $243,173 |
| TrulicityDulaglutide | 186 | $196,144 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 310 | $44,739 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 91 | $40,984 |
| JanuviaSitagliptin Phosphate | 34 | $40,589 |
| RybelsusSemaglutide | 29 | $39,748 |
| Victoza 3-PakLiraglutide | 41 | $38,419 |
| Humalog Kwikpen U-100Insulin Lispro | 135 | $36,797 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $36,506 |
| TradjentaLinagliptin | 37 | $30,536 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 35 | $27,061 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $26,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $8,407 | $827,899779 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $66 | $589,918582 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $4,058 | $281,664276 claims |
| AstraZenecaFarxiga | $44,945 | $271,397236 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $8,667 | $19,20421 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Chaska
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Mark HolmSaint Cloud$318K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
- Maria CastroRochester$63K
- Marius StanRochester$59K
- Matthew DrakeRochester$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.